{"id":"botulinum-toxin-type-a-vistabel","safety":{"commonSideEffects":[{"rate":"null","effect":"Eyelid ptosis"},{"rate":"null","effect":"Diplopia"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Botulinum toxin type A is a neurotoxin that blocks the release of acetylcholine, a neurotransmitter that transmits nerve impulses to muscles, thereby causing muscle relaxation and reducing muscle spasms.","oneSentence":"Inhibits acetylcholine release at the neuromuscular junction","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:57:00.738Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Frown lines"},{"name":"Forehead lines"},{"name":"Crow's feet"}]},"trialDetails":[{"nctId":"NCT05647551","phase":"PHASE4","title":"A Study to Evaluate Satisfaction in Adult Participants With the Aesthetics of the Periorbital Area After JUVÉDERM® Fillers and BOTOX®/VISTABEL® Injections","status":"COMPLETED","sponsor":"AbbVie","startDate":"2023-01-05","conditions":"Facial Corrections, Facial Lines","enrollment":73},{"nctId":"NCT06448676","phase":"PHASE4","title":"Head-to-Head Comparison of All Botulinum Neurotoxin Type A Products for Glabellar Rhytides","status":"NOT_YET_RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2025-01-01","conditions":"Wrinkle","enrollment":200},{"nctId":"NCT05277337","phase":"PHASE4","title":"Study Comparing Treatment With Alluzience vs Reconstituted Toxin","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2022-02-04","conditions":"Glabellar Frown Lines","enrollment":150},{"nctId":"NCT01014871","phase":"PHASE2","title":"Comparison of Two Botulinum Toxins Type A on Forehead Wrinkles","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2009-07","conditions":"Wrinkles","enrollment":30},{"nctId":"NCT04756882","phase":"PHASE2, PHASE3","title":"Clinical Evaluation of the Efficacy OF Botulinum Toxin A for Improving Facial Scars","status":"UNKNOWN","sponsor":"Alexandria University","startDate":"2020-11-18","conditions":"Hypertrophic Scarring","enrollment":12},{"nctId":"NCT01608672","phase":"","title":"Long-Term Patient Satisfaction of Facial Aesthetic Treatment With BOTOX®","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-04-01","conditions":"Glabellar Lines","enrollment":207},{"nctId":"NCT01271452","phase":"PHASE4","title":"Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-09","conditions":"Glabellar Lines","enrollment":224},{"nctId":"NCT01269801","phase":"PHASE4","title":"Study of BOTOX and JUVEDERM for Treatment of Moderate to Severe Facial Wrinkles and Folds","status":"COMPLETED","sponsor":"AboutSkin Dermatology and DermSurgery, PC","startDate":"2011-01","conditions":"Wrinkles","enrollment":156},{"nctId":"NCT00934687","phase":"PHASE2","title":"Botulinum Toxin for the Treatment of Depression","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2009-08","conditions":"Depression","enrollment":30},{"nctId":"NCT01391312","phase":"PHASE4","title":"Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-06","conditions":"Glabellar Frown Lines","enrollment":40},{"nctId":"NCT00777803","phase":"PHASE3","title":"NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines","status":"COMPLETED","sponsor":"Merz Pharmaceuticals GmbH","startDate":"2008-11","conditions":"Glabellar Frown Lines","enrollment":381}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Botulinum Toxin Type A - Vistabel","genericName":"Botulinum Toxin Type A - Vistabel","companyName":"Galderma R&D","companyId":"galderma-r-d","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhibits acetylcholine release at the neuromuscular junction Used for Frown lines, Forehead lines, Crow's feet.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}